Table 4.
Cost Per 1-Year Treatment-Persistent Patient After a Change in Therapy
| Parameter | TNF inhibitor cyclers (N = 6203) | TNF inhibitor-alternative MOA switchers (N = 2640) | Alternative MOA cyclers (N = 699) | Alternative MOA-TNF inhibitor switchers (N = 687) |
|---|---|---|---|---|
| Treatment-persistent patients, N (%) | 2802 (45.2) | 1328 (50.3) P <.001a | 359 (51.4) P = .002a | 317 (46.1) P = .63a |
| Total RA-related cost | ||||
| Mean (SD), $ | 40,898 (19,789) | 37,066 (19,239) P <.001a | 35,375 (20,237) P <.001a | 38,452 (19,294) P = .002a |
| Cost per persistent patient, $ | 90,539 | 73,686 | 68,877 | 83,333 |
| Difference from TNF inhibitor to TNF inhibitor, $ | –16,853 | –21,662 | –7206 | |
| All targeted DMARDs cost | ||||
| Mean (SD), $ | 38,204 (17,718) | 32,845 (17,100) P <.001a | 30,518 (18,354) P <.001a | 35,371 (18,800) P <.001a |
| Cost per persistent patient, $ | 84,574 | 65,294 | 59,421 | 76,655 |
| Difference from TNF inhibitor to TNF inhibitor, $ | –19,280 | –25,153 | –7919 |
a
P value versus TNF inhibitor to TNF inhibitor.
DMARDs indicates disease-modifying antirheumatic drugs; MOA, mechanism of action; RA, rheumatoid arthritis; SD, standard deviation; TNF, tumor necrosis factor.